Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Yian Zhang, Bingzong Li, Junling Zhuang, Pengcheng He, Xingli Zhao, Baijun Fang, Songfu Jiang, Bing Chen, Zhongjun Xia, Zhenyu Li, Zengjun Li, Haifeng Zhao, Dawei Ding, Qianqian Zhang, Xunqiang Wang, Peng Liu

Blood (2025) 146 (Supplement 1): 2279.

https://doi.org/10.1182/blood-2025-2279

Published: 2025

Journal Articles

An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis

Jing Li, Shiyang Gu, Yuhong Ren, Yang Yang, Jiadai Xu, Yian Zhang, Tianhong Xu, Xiaochen Wang, Xiaojiao Zhao, He Xin, Zisong Zhou, Peng Liu

Blood (2025) 146 (Supplement 1): 7674.

https://doi.org/10.1182/blood-2025-7674

Published: 2025

Journal Articles

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Peng Liu, Junling Zhuang, Zhongjun Xia, Bingzong Li, Songfu Jiang, Yian Zhang, Wei Wang, Xiaoqin Chen, Xiaohui Zhang, Shujuan Zhou

Blood (2024) 144 (Supplement 1): 1998.

https://doi.org/10.1182/blood-2024-209665

Published: 2024

Journal Articles

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Yian Zhang, Ling Yuan, Jingli Zhuang, Zhimei Wang, Xuejiao Zhang, Weiguang Wang, Peng Liu

Blood (2023) 142 (Supplement 1): 6304.

https://doi.org/10.1182/blood-2023-185411

Published: 2023

Journal Articles

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Zheng Wei, MD, Yian Zhang, Jing Li, MD, Peng Liu, MD

Blood (2019) 134 (Supplement_1): 1908.

https://doi.org/10.1182/blood-2019-127023

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

An exploratory study to evaluate the safety and efficacy of autologous CAR-T cells with dual targeting of BCMA and CD19 (FKC289 Injection) in subjects with relapsed or refractory systemic light chain amyloidosis

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Zanubrutinib, Polatuzumab Vedotin and Rituximab (ZPR) Combination Regimen for Relapsed/Refractory Patients with Diffuse Large B-Cell Lymphoma

Upfront Ixazomib Plus Dexamethasone Induce Promptly Hematological Response in Patients with Light-Chain Amyloidosis

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only